Eli Lilly in talks to acquire Scorpion Therapeutics, FT says ... - MSN

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. Eli Lilly (NYSE:LLY) is expected to pay around $1 …

$2
OFF

Eli Lilly In Talks To Acquire Scorpion Therapeutics, FT Says ... - MSN

2 weeks from now

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. Eli Lilly (NYSE:LLY) is expected to pay around $1 …

msn.com

$2
OFF

Eli Lilly In Advanced Talks To Buy US Cancer Biotech For Up To $2.5bn

2 weeks from now

4 days ago · Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5bn, according to …

ft.com

$2
OFF

Eli Lilly To Acquire Scorpion Therapeutics’ STX-478 Program For Up …

2 weeks from now

2 days ago · Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says Argus reveals top stock picks for 2025 Drugmakers Raise the Prices on 583 Products to Start 2025

businessinsider.com

$2
OFF

Lilly In Advanced Talks To Buy Cancer Biotech Scorpion For Up To …

2 weeks from now

5 days ago · Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks told Financial Times’ Oliver …

businessinsider.com

$2
OFF

Eli Lilly In Advanced Talks To Buy US Cancer Biotech For Up To $2.5bn

2 weeks from now

5 days ago · Scorpion’s founders include cancer expert Keith Flaherty, the director of clinical research at Massachusetts General Hospital Cancer Center. Flaherty was a co-founder of …

skynews.icu

$2
OFF

Eli Lilly Targets Scorpion Therapeutics To Expand Reach In Oncology

2 weeks from now

1 day ago · Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to …

pharmaceutical-technology.com

$2
OFF

Lilly Close To Acquire Cancer Biotech Scorpion Therapeutics For …

2 weeks from now

4 days ago · -- Eli Lilly is nearing a deal to acquire privately held Scorpion Therapeutics, valuing the Boston-based company working on potential cancer treatments at around $2.5 billion, …

marketscreener.com

$2
OFF

Eli Lilly To Acquire Cancer-Focused Biotech Scorpion Therapeutics …

2 weeks from now

5 days ago · Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5bn. Eli Lilly’s pursuit …

healthcarepress.net

$2
OFF

Eli Lilly In Talks To Acquire Scorpion Therapeutics... | DeepNewz

2 weeks from now

5 days ago · Eli Lilly, the world's largest drugmaker by market value, is in advanced negotiations to acquire Scorpion Therapeutics, a U.S.-based cancer biotech firm, for up to $2.5 billion, …

deepnewz.com

$2
OFF

Lilly Swoops On Morphic To Claim IBD Drug Candidate

2 weeks from now

Jul 8, 2024 · Lilly nets Scorpion cancer drug in $2.5bn licensing deal. Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion …

pharmaphorum.com

$2
OFF

Eli Lilly In Advanced Talks To Buy Us Cancer Biotech Scorpion ...

2 weeks from now

4 days ago · / Eli Lilly In Advanced Talks To Buy Us Cancer Biotech Scorpion The… Eli Lilly In Advanced Talks To Buy Us Cancer Biotech Scorpion Therapeutics For Up To $2.5 Bln- FT. …

tradingview.com

$2
OFF

Eli Lilly Said To Be In Talks To Buy Scorpion Therapeutics For $2.5B

2 weeks from now

5 days ago · Eli Lilly said to be in talks to buy Scorpion Therapeutics for $2.5B Gennaio 10, 2025 0 commenti Eli Lilly and Company is in advanced talks to acquire biotechnology company …

htradingonline.com

$2
OFF

Eli Lilly CEO Tells Bloomberg TV Company Sees Weight Loss Pill …

2 weeks from now

2 days ago · Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B; ... says Barclays; Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says;

businessinsider.com

$2
OFF

Eli Lilly To Acquire Scorpion For Up To $2.5B - One News Page

2 weeks from now

Eli Lilly to acquire Scorpion for up to $2.5B • • Markets • One News Page: Monday, 13 January 2025

onenewspage.com

FAQs about Eli Lilly in talks to acquire Scorpion Therapeutics, FT says ... - MSN Coupon?

Will Eli Lilly buy Scorpion Therapeutics?

Eli Lilly (NYSE: LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. Eli Lilly (NYSE: LLY) is expected to pay around $1 billion upfront for the privately owned Scorpion, according to a Financial Times report on Friday, which cited people familiar with the matter. ...

Is Lilly acquiring Scorpion's pi3kalpha inhibitor program stx-478?

The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kalpha inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. ...

How much would Eli Lilly pay Scorpion?

As part of the proposed terms, Eli Lilly would pay Boston-based Scorpion about $1bn up front followed by up to $1.5bn at a later date if certain performance milestones were met, according to three people familiar with the details. ...

How much money will Lilly pay Scorpion shareholders?

Under the terms of the agreement, Lilly will acquire Scorpion and Scorpion shareholders could receive up to $2.5 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain regulatory and sales milestones. ...

What happened to Relay Therapeutics (rlay)?

Shares of Relay Therapeutics (RLAY), which makes similar technology to Scorpion for fighting cancer, jumped 22% on Lilly news, though has now dropped 10%. Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments. ...

Who are Scorpion's founders?

Its candidate drug is currently in phase-two clinical trials. Scorpion’s founders include cancer expert Keith Flaherty, the director of clinical research at Massachusetts General Hospital Cancer Center. Flaherty was a co-founder of Loxo Oncology, which was bought by Eli Lilly for $8bn in 2019. ...